| Serial Number | 79342262 |
| Word Mark | ILLIMIS THERAPEUTICS |
| Filing Date | Thursday, March 17, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, July 4, 2023 |
| Registration Number | 7095521 |
| Registration Date | Tuesday, July 4, 2023 |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, April 18, 2023 |
| Description of Mark | The mark consists of the wording "ILLIMIS THERAPEUTICS", in stylized font, with the first letter "I", the letters "IMIS" and "THERAPEUTICS" in blue, the first letter "L" in light blue and the second letter "L" in yellow. |
| Certificate of Correction for Registration | In the statement, " International class 42 " is corrected per the restriction dated 5/18/2023 |
| Description of the Colors Claimed | The alphabet "Ill" was expressed with three vertical bars, which is blue, light blue, and yellow. The color part functions as a logo, and the whole including it is pronounced "illimis", the name of the applicant. |
| Goods and Services | Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders |
| Indication of Colors claimed | The color(s) blue, light blue, and yellow is/are claimed as a feature of the mark. |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Pharmaceutical product development; [ pharmaceutical research and development in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady/disease and dysfunction; scientific research in the field of gene therapy; ] medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; [ biotechnology research and scientific and pharmaceutical research in the antibody field; ] biological research; [ scientific research in the field of cancer disease; ] remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; [ scientific and medical research of autoimmune disease; ] development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; * pharmaceutical research and development in the field of age-related diseases, disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady, disease and dysfunction; scientific research for medical purpose in the field of gene therapy; biotechnology research; scientific research for medical purpose in the field of cancer disease; medical research of autoimmune disease; * pharmaceutical research and development in the field of inflammatory disease; pharmaceutical research and development in the field of eye disease; pharmaceutical research and development in the field of amyloidosis; * pharmaceutical * consultancy [ and information ] services relating to pharmaceutical quality control * ; providing information about pharmaceuticals research relating to pharmaceutical quality control * |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 10, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 10, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Illimis Therapeutics, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | Illimis Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | Illimis Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Thursday, June 9, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, June 10, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, June 14, 2022 | APPLICATION FILING RECEIPT MAILED |
| Thursday, December 29, 2022 | ASSIGNED TO EXAMINER |
| Saturday, December 31, 2022 | NON-FINAL ACTION WRITTEN |
| Sunday, January 1, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, February 27, 2023 | REFUSAL PROCESSED BY MPU |
| Monday, February 27, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, March 7, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, March 7, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, March 7, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, March 11, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, March 21, 2023 | REFUSAL PROCESSED BY IB |
| Wednesday, March 29, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, April 5, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, April 5, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Tuesday, April 18, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 18, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 25, 2023 | NOTIFICATION PROCESSED BY IB |
| Sunday, May 21, 2023 | LIMITATION OF GOODS RECEIVED FROM IB |
| Tuesday, July 4, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, July 4, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Saturday, October 14, 2023 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Wednesday, October 4, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Saturday, October 14, 2023 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Saturday, October 14, 2023 | CORRECTION UNDER SECTION 7 - PROCESSED |
| Tuesday, November 21, 2023 | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED |
| Monday, October 16, 2023 | LIMITATION FROM THE IB EXAMINED AND ENTERED |
| Tuesday, January 16, 2024 | FINAL DISPOSITION PROCESSED |
| Wednesday, July 24, 2024 | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE |
| Tuesday, June 18, 2024 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Tuesday, January 16, 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| Tuesday, February 6, 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |